36,766 Shares in Medtronic PLC $MDT Acquired by Knights of Columbus Asset Advisors LLC

Knights of Columbus Asset Advisors LLC purchased a new position in shares of Medtronic PLC (NYSE:MDT) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 36,766 shares of the medical technology company’s stock, valued at approximately $3,173,000.

A number of other hedge funds have also bought and sold shares of the business. BlackRock Inc. grew its stake in Medtronic by 0.7% in the 2nd quarter. BlackRock Inc. now owns 114,020,787 shares of the medical technology company’s stock valued at $8,919,846,000 after purchasing an additional 838,220 shares during the period. State Street Corp increased its position in shares of Medtronic by 2.7% during the 2nd quarter. State Street Corp now owns 63,399,315 shares of the medical technology company’s stock valued at $5,005,320,000 after purchasing an additional 1,658,301 shares during the last quarter. Bank of America Corp DE raised its stake in shares of Medtronic by 5.4% during the 1st quarter. Bank of America Corp DE now owns 26,015,003 shares of the medical technology company’s stock worth $2,254,200,000 after purchasing an additional 1,343,220 shares during the period. First Eagle Investment Management LLC raised its stake in shares of Medtronic by 37.2% during the 2nd quarter. First Eagle Investment Management LLC now owns 13,783,983 shares of the medical technology company’s stock worth $1,078,321,000 after purchasing an additional 3,739,288 shares during the period. Finally, WCM Investment Management LLC purchased a new position in shares of Medtronic in the 1st quarter worth about $965,922,000. 82.06% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms recently weighed in on MDT. Weiss Ratings upgraded shares of Medtronic from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, October 19th. Deutsche Bank reaffirmed a “hold” rating and issued a $92.00 price objective on shares of Medtronic in a research report on Thursday, September 3rd. Robert W. Baird lifted their price objective on shares of Medtronic from $91.00 to $100.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 2nd. UBS Group reiterated a “cautious” rating on shares of Medtronic in a research note on Wednesday, October 14th. Finally, Needham & Company LLC reissued a “buy” rating on shares of Medtronic in a research report on Thursday, September 17th. Eighteen analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Medtronic currently has a consensus rating of “Moderate Buy” and an average target price of $102.88.

Key Headlines Impacting Medtronic

These are some of the MDT headlines that stood out recently:

• Positive Sentiment: Medtronic launched a micro guidewire for neurovascular procedures, expanding its product offering in that market. Article: Medtronic launches micro guidewire for neurovascular procedures
• Positive Sentiment: Reported short interest fell 83.5% in October to about 22.95 million shares, or roughly 1.8% of shares outstanding. That suggests fewer investors were positioned for a decline, though short-interest data alone does not indicate future performance. Article: Medtronic PLC Shares Shorted: Short Interest Down 83.5% in October
• Neutral Sentiment: A collaborative cardiac-therapy trial involving Medtronic has completed enrollment with 349 patients. Results are expected to be presented at Heart Rhythm Society 2027; a planned FDA submission depends on positive data, so the potential benefit remains uncertain. Article: Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates

Insider Transactions at Medtronic

In other news, EVP Michael Marinaro sold 10,420 shares of Medtronic stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $96.00, for a total value of $1,000,320.00. Following the completion of the transaction, the executive vice president owned 105,916 shares in the company, valued at $10,167,936. This trade represents a 8.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Harry Kiil sold 1,483 shares of the business’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total transaction of $138,882.95. Following the completion of the sale, the executive vice president directly owned 42,186 shares in the company, valued at approximately $3,950,718.90. This trade represents a 3.40% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 61,903 shares of company stock worth $5,889,203 over the last quarter. Corporate insiders own 0.27% of the company’s stock.

Medtronic Stock Performance

Shares of MDT opened at $101.64 on Thursday. Medtronic PLC has a 1 year low of $73.31 and a 1 year high of $106.33. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54. The stock’s fifty day moving average price is $93.34 and its two-hundred day moving average price is $88.46. The firm has a market cap of $130.01 billion, a PE ratio of 17.76, a PEG ratio of 2.38 and a beta of 0.56.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, topping the consensus estimate of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The company had revenue of $9.76 billion during the quarter, compared to analyst estimates of $9.55 billion. During the same quarter last year, the firm posted $1.26 EPS. The firm’s revenue for the quarter was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, equities research analysts forecast that Medtronic PLC will post 5.98 EPS for the current year.

Medtronic Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, October 16th. Shareholders of record on Friday, September 25th were given a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date was Friday, September 25th. Medtronic’s dividend payout ratio (DPR) is currently 70.94%.

Medtronic Company Profile

Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.